NSE filing, NSE: THYROCARE. Summary written from the filing by ALFA Finder's alert engine.
Thyrocare Technologies Ltd: key numbers
- Share price
- ₹514.95
- Market cap
- ₹8,196 Cr
- Revenue (annual)
- ₹829.0 Cr
- Net profit (annual)
- ₹163.0 Cr
- P/E (TTM)
- 46.5×Sector 52.0×
- Promoter holding
- 51.02%-9.90% QoQ
- FII holding
- 9.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Thyrocare Technologies Ltd
All →Thyrocare Technologies Board Meeting Date
Thyrocare Technologies intimated that its Board meeting is scheduled for 29 Oct 2026 to consider Q2/H1 FY27 results. No financial figures or decisions are reported in this prior intimation.
Thyrocare Technologies Other Announcement
Thyrocare Technologies filed its quarterly shareholding pattern for the period ended September 30, 2026, including a note regarding a prior promoter group amalgamation.
Thyrocare Technologies Annual General Meeting
Thyrocare Technologies initiated a postal ballot for two resolutions: purchasing property from its subsidiary, Nueclear Healthcare, and selling its investment in Nueclear Healthcare.
Thyrocare Technologies Annual General Meeting
Thyrocare seeks shareholder approval via postal ballot for the purchase of land and building and the divestment of its subsidiary, Nueclear Healthcare Limited.
- Value
- ₹162.0 Cr
Thyrocare Technologies Employee Stock Options
Thyrocare Technologies Limited has granted 1,92,000 employee stock options to eligible employees under the company's approved stock option scheme.
Thyrocare Technologies Merger & Restructuring Worth ₹141.4 Cr
Thyrocare's board approved sale of 100% in Nueclear Healthcare to Trovera for ~₹141.40 Crore. The move exits radiology to refocus on core pathology business.
- Value
- ₹141.4 Cr
- Execution
- On or before November 30, 2026
Other board meeting date announcements
All →Mahaveer Infoway Board Meeting Date
Mahaveer Infoway Ltd scheduled a board meeting for 3 Nov 2026 to approve Q1 FY27 unaudited results and the limited review report. This is a routine prior intimation under Reg 29(1)(a).
Indowind Energy Board Meeting Date
Indowind Energy scheduled a board meeting on 5 Nov 2026 to approve Q1 FY27 unaudited results. The trading window remains closed until 48 hours post-approval.
Dhunseri Ventures Board Meeting Date
Dhunseri Ventures Ltd intimated that its Board will meet on 6 November 2026, inter alia to approve Q2 FY27 results. The trading window stays closed until 8 November 2026.
CESC Board Meeting Date
CESC Ltd scheduled its Board Meeting for 5 Nov 2026 to consider Q2/H1 FY27 unaudited results. No financial figures or decisions are reported in this advance intimation.
Genpharmasec Board Meeting Date
Genpharmasec Ltd will hold a Board meeting on 03 Nov 2026. Agenda includes proposing approval of Q2/H1 FY27 unaudited results.
Hexa Tradex Board Meeting Date
Hexa Tradex scheduled its board meeting for November 5, 2026, to approve Q2 FY27 unaudited financial results. Trading window closes until 48 hours post-disclosure.